Revvity (RVTY) has just introduced its SuperFlex prenatal screening system, a compact CE IVDR certified immunoassay platform aimed at lower volume labs, while investors also digest the company’s recent second quarter earnings update.

Revvity’s latest SuperFlex launch and steady second quarter earnings come against a backdrop of stronger momentum, with a 90 day share price return of 21.17% and a 1 year total shareholder return of 29.88%. However, the 5 year total shareholder return shows a decline of 35.23%.

If this kind of diagnostics focused story interests you, it can be useful to see what else is moving in related areas and uncover 40 healthcare AI stocks.

After a 21.17% move over 90 days and a 29.88% total return over 1 year, investors now need to decide whether Revvity’s recent momentum already reflects its prospects or if the current valuation still leaves meaningful upside ahead.

Most Popular Narrative: 4% Undervalued

Revvity’s most followed valuation narrative points to a fair value of about $121.07 compared with the last close at $116.17, which frames today’s discussion around a modest discount rather than a deep value gap.

Ongoing shift in product mix toward higher-margin, software-enabled and consumables-driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.

The core of this narrative is a margin reset, not just a revenue story. It leans heavily on improving profitability, rising earnings power and a valuation multiple that steps down from today’s level yet still supports that higher fair value.

Result: Fair Value of $121.07 (UNDERVALUED)

However, investors also need to watch for pressure from healthcare cost controls in key markets, as well as any prolonged weakness in academic or government funding that could weigh on Revvity.

Another View on Revvity’s Valuation

The analyst narrative frames Revvity as modestly undervalued, yet the current P/E of 54.6x tells a different story. It is higher than the estimated fair ratio of 27.5x, the US Life Sciences peer average of 40x, and the global industry average of 36.9x. That gap could indicate valuation risk if sentiment cools, so the question becomes how comfortable you are paying this premium for the growth on offer.

Next Steps

With mixed signals on valuation and fundamentals around Revvity, it makes sense to review the numbers yourself and move quickly to a clear view. A useful starting point is our breakdown of 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Revvity?

You do not need to stop with Revvity. Use targeted stock lists to quickly spot fresh ideas that match your risk level and return goals.

• Target resilient potential by checking out 80 resilient stocks with low risk scores that may hold up better when markets get choppy.
• Hunt for quality at a discount through screener containing 19 high quality undiscovered gems that many investors may have overlooked so far.
• Prioritise balance sheet strength with the solid balance sheet and fundamentals stocks screener (50 results) so you are not caught off guard by hidden financial weakness.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.